Revolution Medicines announced that its drug, daraxonrasib, successfully completed a Phase 3 clinical trial for pancreatic cancer, demonstrating a significant increase in patient survival rates compared to standard chemotherapy.
Trial Efficacy and Survival Data
According to the company, the daily pill, daraxonrasib, met all primary and secondary endpoints in a trial involving patients whose cancer had progressed after receiving other treatments. The results indicate a substantial improvement in overall survival:
- Daraxonrasib Group: Patients typically lived for 13.2 months.
- Chemotherapy Group: Patients typically lived for 6.7 months.
This represents an increase of 6.5 months in overall survival, a finding the company described as "dramatic, practice-changing outcomes."
Mechanism of Action and Significance
Daraxonrasib is designed to target RAS mutations, which are identified as the driving force behind tumor growth in approximately 90% of pancreatic cancer cases. The drug's efficacy is particularly notable given that pancreatic cancer has one of the lowest five-year survival rates of any major cancer, currently sitting at 13%.
CEO Mark Goldsmith stated that these results "usher in a new era of RAS-targeted medicines for pancreatic cancer, which has historically been treated exclusively with cytotoxic intravenous chemotherapy."
Regulatory Status and Safety Profile
Revolution Medicines plans to seek approval from the Food and Drug Administration (FDA) soon, utilizing a Commissioner's National Priority Voucher to expedite the review process. The company is currently seeking approval for second-line treatment—meaning patients whose cancer has already spread while undergoing another drug regimen.
Regarding safety, the drug demonstrated a manageable safety profile, and the company noted that a rash is a known, generally manageable side effect.
Market Reaction
Following the release of the positive trial results on Monday, Revolution Medicines' shares increased by more than 30% on the stock market.
